Diagnosis and treatment of metastatic and castration resistant prostate cancer became more and more and complex due to the increasing knowledge and understanding of the underlying molecular events and the subsequently deducted innovative medical treatment.
Modern imaging studies in CRPC have become more selective and currently include positron emission tomography, whole body magnetic resonance imaging, immunoscintigraphy besides the traditional studies such as bone scans and computed tomography.
New expert interviews, 29th June, 2015, Amsterdam, The Netherlands
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): A phase 3 randomised controlled trial
Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, et al.Lancet Oncol. 2015 Jul;16(7):787-94.
Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: A tertiary academic center experience
Afshar M, Evison F, James ND, Patel PUrol Oncol. 2015 Jun 6. [Epub ahead of print]
Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
Cheng HH, Gulati R, Azad A, Nadal R, Twardowski P, Vaishampayan UN, et alProstate Cancer Prostatic Dis. 2015 Jun;18(2):122-7
Improvements in radiographic progression-free survival stratified by ERG gene status in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate
Attard G, De Bono JS, Logothetis CJ, Fizazi K, Mukherjee SD, Joshua AM, et al.Clin Cancer Res. 2015 Apr 1;21(7):1621-7.
About the editors
- Professor Miller has been Chairman and Professor of Urology for the Department of Urology at the Benjamin Franklin Medical Center, Berlin, Germany, since 1993. In 2007 he became Chairman of the Department of Urology for the entire Charité (Campus Benjamin Franklin, Campus Mitte and Campus Virchow Klinikum). With more than 6000 in-patients per year, the Dep. of Urology at the Charité is one the largest urologicals clinics in Europe.
- Prof Axel S. Merseburger is currently Chairman of the Clinic of Urology at University Hospital Schleswig-Holstein in Lübeck, Germany, having previously served as Vice Chairman of the Department of Urologic Oncology and Director of the Urologic Oncology Programme at Hannover Medical School, Germany. Professor Merseburger obtained his medical degree from Hannover Medical School in 2002 following a 1-year academic research programme in Washington D.C., USA, where he finished his M.D. thesis.
- Jun 201528Jul 201530Contact: ICS Offi ce Tel.: +44 117 944 4881 Fax: +44 117 944 4882 E-mail: info@icsoffi ce.org
- Aug 201517Aug 201521The Prostate Cancer World Congress is the world’s largest multidisciplinary prostate cancer meeting. In August 2015, World Leaders will meet...